John Strouse: Grateful for ASH’s Support and for the Privilege of Working with Charity Oyedeji
John Strouse, Associate Professor of Medicine at Duke University Medical Center, shared on LinkedIn:
“I am glad that ASH exists to support researchers through this time of unprecedented disruption to research and the healthcare in the United States and that I have the privilege of working with Charity Oyedeji!”
Quoting American Society of Hematology’s post:
“This past summer, the National Institutes of Health cut funding for a sickle cell disease initiative led by Charity Oyedeji, before it was complete. The Sickle Cell Disease (SCD) Functional Assessment Validation and Refinement (SILVR) Study and the SickleFit Exercise Program were focusing on physical capabilities and independence for patients with SCD. Beyond disrupting patient care, such funding cuts may also discourage researchers, particularly those from underrepresented backgrounds, from pursuing vital work in hematology and SCD research.
Learn more and help protect critical research in hematology here.”
Get the latest ASH updates on Hemostasis Today.
-
May 26, 2026, 03:02Spelile Mutupira: Process of Blood Clotting After Injury
-
May 26, 2026, 03:00Clinton Otwori: Which Blood Product Do Healthcare Workers Most Commonly Misunderstand in Practice?
-
May 26, 2026, 02:58Toriqul Islam: EDTA-Induced Pseudothrombocytopenia
-
May 26, 2026, 02:34James O’Donnell Secures 2 Million Euros for a New Programme on The Irish ABO and Coagulation Study – RCSI
-
May 26, 2026, 02:26Joseph R. Shaw: Join The Annual CanVECTOR National Thrombosis Seminar on Precision in DOAC Reversal
-
May 26, 2026, 01:42Mili Doshi: The Role of Oral Health Teams in Supporting Stroke Rehabilitation and Recovery
-
May 26, 2026, 01:25Mohamed Mamdouh: Advancing Stroke Care Access in Cairo Through the Launch of a New Stroke-Ready Center
-
May 26, 2026, 01:15Tom Lazenby: Accelerating Rare Disease Drug Development Through MHRA’s Investigational Marketing Authorisation
-
May 25, 2026, 22:15Cedric Hermans: What Is Still To Be Discovered and To Be Redefined in The Treatment of Haemophilia A?